查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2147163

血漿分餾市場規模、佔有率、成長、全球產業分析、區域趨勢及2026年至2034年預測。

Plasma Fractionation Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

血漿分餾市場的成長要素

2025年全球血漿分餾市場價值為402.7億美元。預計該市場將從2026年的435.5億美元成長到2034年的872.3億美元，2026年至2034年的複合年成長率為9.1%。北美在2025年以56.22%的市場佔有率引領全球市場，這主要得益於其強大的血漿採集基礎設施、免疫球蛋白療法的高普及率以及針對罕見疾病和免疫疾病的成熟治療途徑。

血漿分餾是將人類血漿分離成治療性蛋白質的過程，例如免疫球蛋白、白蛋白、凝血因子和蛋白酶抑制劑。這些產品對於滿足免疫力缺乏、神經系統疾病、出血性疾病、代謝性疾病和重症監護的需求至關重要。診斷率的提高和對長期血漿衍生療法需求的成長正在推動市場成長。

血漿分餾市場趨勢

市場主要趨勢之一是各國日益重視血漿自給自足。各國政府和醫療衛生系統正努力透過加強國內血液採集和分離能力，減少對進口血漿衍生藥品的依賴。

2024年6月，武田製藥公司宣布投資2.3億美元，擴大其位於洛杉磯的製造地血漿衍生療法產品的產能。這將有助於提高罕見疾病、慢性病和遺傳性疾病治療藥物的供應。

市場促進因素

市場的主要促進因素是免疫力缺乏、自體免疫疾病、神經系統疾病和罕見疾病的盛行率不斷上升。許多患者需要定期或終身接受免疫球蛋白和其他血漿衍生藥物的治療。

2025年6月，武田製藥公司獲得美國食品藥物管理局（FDA）批准，其產品GAMMAGARD LIQUID ERC用於治療2歲以上原發性免疫力缺乏患者。此類批准擴大了治療途徑，並增加了對血漿衍生產品的需求。

市場限制與挑戰

血漿供應有限以及對人類捐贈者的嚴重依賴仍然是主要阻礙因素。血漿衍生藥品需要持續的捐贈者供應，但加工、純化、檢測、病毒去活化以及獲得監管部門批准上市等環節可能需要數月時間。

生產流程的複雜性是另一項挑戰。根據本報告引用的數據，血漿衍生藥物的生產可能需要7到12個月，這使得快速應對臨床需求的激增變得困難。

市場機遇

擴大血漿採集中心規模並提高血漿分離能力蘊藏著巨大的機會。大規模的採集網路可以增強供應穩定性，並緩解免疫球蛋白、白蛋白和凝血因子的短缺問題。

2024 年，Grifors 公司投資 1.806 億美元在西班牙里卡德瓦爾新建了一家製造工廠，旨在將其在歐洲的血漿分餾能力翻倍。

細分分析

按產品類別分類，免疫球蛋白市場佔據主導地位，這主要得益於其在原發性免疫力缺乏、續發性免疫力缺乏、自體免疫疾病和神經系統疾病中的廣泛應用。白蛋白市場預計將以7.8%的複合年成長率成長。

按應用領域分類，免疫學領域佔據最大佔有率，這主要得益於常規免疫球蛋白替代療法。血液學領域預計將以9.1%的複合年成長率成長。

按終端用戶分類，到2025年，醫院和診所將佔據市場主導地位，因為許多基於血漿的療法需要醫生監督、液體支持和臨床監測。預計居家醫療產業將以10.2%的複合年成長率實現最高成長。

區域展望

預計到2025年，北美將以226.4億美元的市場規模佔據領先地位。預計到2026年，美國市場規模將達到約226.6億美元。

預計到 2026 年，歐洲的經濟規模將達到 91.1 億美元，其中德國預計將佔約 19 億美元，英國預計將佔 14.6 億美元。

預計到 2026 年，亞太地區的經濟規模將達到 84.8 億美元。其中，中國預計將達到 37.2 億美元，日本將達到 22.9 億美元，印度將達到 10.3 億美元。

預計到 2026 年，拉丁美洲市場規模將達到 9,800 萬美元，而海灣合作理事會市場規模估計為 2,100 萬美元。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
  • 市場趨勢

第4章：主要考慮因素

  • 大型公司的血漿分餾能力
  • 主要國家血漿採集中心數量
  • 主要國家血漿分離成本細分
  • 血漿分餾處理量的區域分佈
  • 主要國家慢性病盛行率（主要指標）
  • 主要國家血漿分餾產品價格分析
  • 主要國家的監管趨勢
  • 概述：血漿採集技術
  • 大型公司管道分析
  • 主要產業趨勢（合併、收購、合作等）
  • 波特五力分析
  • PESTLE分析
  • 價值鏈分析
  • 價格趨勢分析

第5章：2021-2034年全球血漿分餾市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品分類。
    • 白蛋白
    • 免疫球蛋白
      • 靜脈注射免疫球蛋白
      • 皮下注射免疫球蛋白
    • 凝血因子
      • 因子九
      • 因子 VIII
      • 凝血酶原複合物濃縮物
      • 纖維蛋白原濃縮物
      • 血管性血友病因子
      • 抗凝血酶
      • 其他
    • 蛋白酶抑制劑
      • α-1抗胰蛋白酶
      • C1酯酶抑制劑
      • 其他
    • 其他
  • 市場分析、洞察與預測：按應用領域分類
    • 免疫學
    • 神經病學
    • 血液學
    • 重症加護
    • 呼吸內科
    • 感染疾病
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和診所
    • 專科診所及靜脈輸液治療中心
    • 居家照護環境
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美血漿分餾市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲血漿分餾市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區血漿分餾市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲血漿分餾市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲血漿分餾市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2024 年）
  • 公司簡介
    • CSL
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Kedrion SpA
    • LFB Group
    • ADMA Biologics, Inc.
    • GC Biopharma corporate
    • Beijing Tiantan Biological Products Co., Ltd.
    • Shanghai RAAS Blood Products Co., Ltd.
Product Code: FBI101614

Growth Factors of plasma fractionation Market

The global plasma fractionation market size was valued at USD 40.27 billion in 2025. The market is projected to grow from USD 43.55 billion in 2026 to USD 87.23 billion by 2034, exhibiting a CAGR of 9.1% during 2026-2034. North America dominated the global market with a 56.22% share in 2025, supported by strong plasma collection infrastructure, high use of immunoglobulin therapies, and well-established treatment access for rare and immune disorders.

Plasma fractionation separates human plasma into therapeutic proteins such as immunoglobulins, albumin, coagulation factors, and protease inhibitors. These products are essential for treating immune deficiencies, neurological disorders, bleeding conditions, metabolic deficiencies, and critical-care needs. Rising diagnosis rates and increasing demand for long-term plasma-derived therapies are supporting market growth.

Plasma Fractionation Market Trends

A major market trend is the growing focus on national plasma self-sufficiency. Governments and healthcare systems are working to reduce dependence on imported plasma-derived medicines by strengthening domestic collection and fractionation capabilities.

In June 2024, Takeda announced a USD 230 million investment to expand plasma-derived therapy production capacity at its Los Angeles manufacturing site, supporting greater availability of treatments for rare, chronic, and genetic diseases.

Market Drivers

The major market driver is the rising prevalence of immune deficiencies, autoimmune disorders, neurological conditions, and rare diseases. Many patients require recurring or lifelong treatment with immunoglobulins or other plasma-derived medicines.

In June 2025, Takeda received U.S. FDA approval for GAMMAGARD LIQUID ERC for patients aged two years and older with primary immunodeficiency. Such approvals are widening treatment access and strengthening demand for plasma-derived products.

Market Restraints and Challenges

Limited plasma availability and strong dependence on human donors remain major restraints. Plasma-derived medicines require a continuous donor supply, while processing, purification, testing, viral inactivation, and regulatory release can take several months.

Manufacturing complexity is another challenge. According to data cited in the report, plasma-derived medicines can require 7-12 months to produce, making it difficult to respond quickly to sudden increases in clinical demand.

Market Opportunities

The expansion of plasma collection centers and fractionation capacity offers significant opportunities. Larger collection networks can improve supply security and reduce shortages of immunoglobulins, albumin, and coagulation factors.

In 2024, Grifols invested USD 180.6 million in a new manufacturing facility in Llica de Vall, Spain, designed to double its plasma fractionation capacity in Europe.

Segmentation Analysis

By product, the immunoglobulin segment dominated the market, supported by extensive use in primary immunodeficiency, secondary immunodeficiency, autoimmune disorders, and neurological diseases. The albumin segment is projected to grow at a 7.8% CAGR.

By application, immunology held the leading share, driven by recurring immunoglobulin replacement therapies. The hematology segment is expected to grow at a 9.1% CAGR.

By end user, hospitals & clinics dominated in 2025, as many plasma-derived therapies require physician supervision, infusion support, and clinical monitoring. Homecare settings are projected to record the fastest 10.2% CAGR.

Regional Outlook

North America dominated with a market value of USD 22.64 billion in 2025. The U.S. market is estimated to reach approximately USD 22.66 billion in 2026.

Europe is projected to reach USD 9.11 billion in 2026, with Germany at approximately USD 1.90 billion and the U.K. at USD 1.46 billion.

Asia Pacific is estimated to reach USD 8.48 billion in 2026. China is projected at USD 3.72 billion, Japan at USD 2.29 billion, and India at USD 1.03 billion.

Latin America is projected to reach USD 0.98 billion in 2026, while the GCC market is estimated at USD 0.21 billion.

Competitive Landscape

Major companies include CSL, Grifols, Takeda Pharmaceutical, Octapharma, Kedrion, LFB Group, ADMA Biologics, GC Biopharma, Beijing Tiantan Biological Products, and Shanghai RAAS Blood Products. Competition centers on plasma collection expansion, new product approvals, manufacturing capacity, portfolio diversification, and regional supply partnerships.

Key Industry Developments

In December 2025, Grifols received U.S. FDA approval for FESILTY for congenital fibrinogen deficiency. In November 2025, Baiyang Pharmaceutical collaborated with CSL Behring for promotion and distribution of selected plasma-derived products in China. In July 2024, Kedrion partnered with Portugal's IPST to fractionate locally donated plasma.

Conclusion

The plasma fractionation market is expected to grow from USD 40.27 billion in 2025 to USD 43.55 billion in 2026 and USD 87.23 billion by 2034, at a CAGR of 9.1% during 2026-2034. Growth will be driven by rising immunoglobulin demand, increasing diagnosis of rare and immune disorders, plasma self-sufficiency initiatives, and expansion of collection and manufacturing capacity. However, donor dependency, limited plasma availability, and lengthy production timelines may constrain supply. North America is expected to retain its leading position, while Europe and Asia Pacific continue expanding plasma collection and treatment access.

Segmentation By Product, Application, End User, and Region

By Product

  • Albumin
  • Immunoglobulin
    • Intravenous Immunoglobulin
    • Subcutaneous Immunoglobulin
  • Coagulation Factors
    • Factor IX
    • Factor VIII
    • Prothrombin Complex Concentrates
    • Fibrinogen Concentrates
    • von Willebrand Factor
    • Antithrombin
    • Others
  • Protease Inhibitors
    • Alpha-1 Antitrypsin
    • C1 Esterase Inhibitor
    • Others
  • Others

By Application

  • Immunology
  • Neurology
  • Hematology
  • Critical Care
  • Pulmonology
  • Infectious Disease
  • Others

By End User

  • Hospitals & Clinics
  • Specialty Clinics & Infusion Centers
  • Homecare Settings
  • Others

By Region

  • North America (By Product, Application, End User, and Country)
    • U.S. (Product)
    • Canada (Product)
  • Europe (By Product, Application, End User, and Country/Sub-region)
    • Germany (Product)
    • U.K. (Product)
    • France (Product)
    • Spain (Product)
    • Italy (Product)
    • Scandinavia (Product)
    • Rest of Europe (Product)
  • Asia Pacific (By Product, Application, End User, and Country/Sub-region)
    • China (Product)
    • Japan (Product)
    • India (Product)
    • Australia (Product)
    • Southeast Asia (Product)
    • Rest of Asia Pacific (Product)
  • Latin America (By Product, Application, End User, and Country/Sub-region)
    • Brazil (Product)
    • Mexico (Product)
    • Rest of Latin America (Product)
  • Middle East & Africa (By Product, Application, End User, and Country/Sub-region)
    • GCC (Product)
    • South Africa (Product)
    • Rest of Middle East & Africa (Product)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Challenges
  • 3.5. Market Trends

4. Key Insights

  • 4.1. Plasma Fractionation Capacity, By Key Players
  • 4.2. Number of Plasma Collection Centers, By Key Countries
  • 4.3. Cost Breakdown of Plasma Fractionation, By Key Countries
  • 4.4. Regional Distribution of Plasma Fractionation Throughput
  • 4.5. Prevalence of Chronic Diseases (Key Indications), By Key Countries
  • 4.6. Pricing Analysis, Plasma Fractionated Products, By Key Countries
  • 4.7. Regulatory Scenario, By Key Countries
  • 4.8. Overview : Plasma Collection Technologies
  • 4.9. Pipeline Analysis, By Key Companies
  • 4.10. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.11. Porter's Five Forces Analysis
  • 4.12. PESTEL Analysis
  • 4.13. Value Chain Analysis
  • 4.14. Price Trend Analysis

5. Global Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Albumin
    • 5.1.2. Immunoglobulin
      • 5.1.2.1. Intravenous Immunoglobulin
      • 5.1.2.2. Subcutaneous Immunoglobulin
    • 5.1.3. Coagulation Factors
      • 5.1.3.1. Factor IX
      • 5.1.3.2. Factor VIII
      • 5.1.3.3. Prothrombin Complex Concentrates
      • 5.1.3.4. Fibrinogen Concentrates
      • 5.1.3.5. von Willebrand Factor
      • 5.1.3.6. Antithrombin
      • 5.1.3.7. Others
    • 5.1.4. Protease Inhibitors
      • 5.1.4.1. Alpha-1 Antitrypsin
      • 5.1.4.2. C1 Esterase Inhibitor
      • 5.1.4.3. Others
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Immunology
    • 5.2.2. Neurology
    • 5.2.3. Hematology
    • 5.2.4. Critical Care
    • 5.2.5. Pulmonology
    • 5.2.6. Infectious Disease
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & Clinics
    • 5.3.2. Specialty Clinics & Infusion Centers
    • 5.3.3. Homecare Settings
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Albumin
    • 6.1.2. Immunoglobulin
      • 6.1.2.1. Intravenous Immunoglobulin
      • 6.1.2.2. Subcutaneous Immunoglobulin
    • 6.1.3. Coagulation Factors
      • 6.1.3.1. Factor IX
      • 6.1.3.2. Factor VIII
      • 6.1.3.3. Prothrombin Complex Concentrates
      • 6.1.3.4. Fibrinogen Concentrates
      • 6.1.3.5. von Willebrand Factor
      • 6.1.3.6. Antithrombin
      • 6.1.3.7. Others
    • 6.1.4. Protease Inhibitors
      • 6.1.4.1. Alpha-1 Antitrypsin
      • 6.1.4.2. C1 Esterase Inhibitor
      • 6.1.4.3. Others
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Immunology
    • 6.2.2. Neurology
    • 6.2.3. Hematology
    • 6.2.4. Critical Care
    • 6.2.5. Pulmonology
    • 6.2.6. Infectious Disease
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & Clinics
    • 6.3.2. Specialty Clinics & Infusion Centers
    • 6.3.3. Homecare Settings
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Product
    • 6.4.2. Canada
      • 6.4.2.1. By Product

7. Europe Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Albumin
    • 7.1.2. Immunoglobulin
      • 7.1.2.1. Intravenous Immunoglobulin
      • 7.1.2.2. Subcutaneous Immunoglobulin
    • 7.1.3. Coagulation Factors
      • 7.1.3.1. Factor IX
      • 7.1.3.2. Factor VIII
      • 7.1.3.3. Prothrombin Complex Concentrates
      • 7.1.3.4. Fibrinogen Concentrates
      • 7.1.3.5. von Willebrand Factor
      • 7.1.3.6. Antithrombin
      • 7.1.3.7. Others
    • 7.1.4. Protease Inhibitors
      • 7.1.4.1. Alpha-1 Antitrypsin
      • 7.1.4.2. C1 Esterase Inhibitor
      • 7.1.4.3. Others
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Immunology
    • 7.2.2. Neurology
    • 7.2.3. Hematology
    • 7.2.4. Critical Care
    • 7.2.5. Pulmonology
    • 7.2.6. Infectious Disease
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & Clinics
    • 7.3.2. Specialty Clinics & Infusion Centers
    • 7.3.3. Homecare Settings
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
      • 7.4.1.1. By Product
    • 7.4.2. Germany
      • 7.4.2.1. By Product
    • 7.4.3. France
      • 7.4.3.1. By Product
    • 7.4.4. Spain
      • 7.4.4.1. By Product
    • 7.4.5. Italy
      • 7.4.5.1. By Product
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Product
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Product

8. Asia Pacific Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Albumin
    • 8.1.2. Immunoglobulin
      • 8.1.2.1. Intravenous Immunoglobulin
      • 8.1.2.2. Subcutaneous Immunoglobulin
    • 8.1.3. Coagulation Factors
      • 8.1.3.1. Factor IX
      • 8.1.3.2. Factor VIII
      • 8.1.3.3. Prothrombin Complex Concentrates
      • 8.1.3.4. Fibrinogen Concentrates
      • 8.1.3.5. von Willebrand Factor
      • 8.1.3.6. Antithrombin
      • 8.1.3.7. Others
    • 8.1.4. Protease Inhibitors
      • 8.1.4.1. Alpha-1 Antitrypsin
      • 8.1.4.2. C1 Esterase Inhibitor
      • 8.1.4.3. Others
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Immunology
    • 8.2.2. Neurology
    • 8.2.3. Hematology
    • 8.2.4. Critical Care
    • 8.2.5. Pulmonology
    • 8.2.6. Infectious Disease
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & Clinics
    • 8.3.2. Specialty Clinics & Infusion Centers
    • 8.3.3. Homecare Settings
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
      • 8.4.1.1. By Product
    • 8.4.2. China
      • 8.4.2.1. By Product
    • 8.4.3. India
      • 8.4.3.1. By Product
    • 8.4.4. Australia
      • 8.4.4.1. By Product
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Product
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Product

9. Latin America Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Albumin
    • 9.1.2. Immunoglobulin
      • 9.1.2.1. Intravenous Immunoglobulin
      • 9.1.2.2. Subcutaneous Immunoglobulin
    • 9.1.3. Coagulation Factors
      • 9.1.3.1. Factor IX
      • 9.1.3.2. Factor VIII
      • 9.1.3.3. Prothrombin Complex Concentrates
      • 9.1.3.4. Fibrinogen Concentrates
      • 9.1.3.5. von Willebrand Factor
      • 9.1.3.6. Antithrombin
      • 9.1.3.7. Others
    • 9.1.4. Protease Inhibitors
      • 9.1.4.1. Alpha-1 Antitrypsin
      • 9.1.4.2. C1 Esterase Inhibitor
      • 9.1.4.3. Others
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Immunology
    • 9.2.2. Neurology
    • 9.2.3. Hematology
    • 9.2.4. Critical Care
    • 9.2.5. Pulmonology
    • 9.2.6. Infectious Disease
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & Clinics
    • 9.3.2. Specialty Clinics & Infusion Centers
    • 9.3.3. Homecare Settings
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
      • 9.4.1.1. By Product
    • 9.4.2. Mexico
      • 9.4.2.1. By Product
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Product

10. Middle East & Africa Plasma Fractionation Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Albumin
    • 10.1.2. Immunoglobulin
      • 10.1.2.1. Intravenous Immunoglobulin
      • 10.1.2.2. Subcutaneous Immunoglobulin
    • 10.1.3. Coagulation Factors
      • 10.1.3.1. Factor IX
      • 10.1.3.2. Factor VIII
      • 10.1.3.3. Prothrombin Complex Concentrates
      • 10.1.3.4. Fibrinogen Concentrates
      • 10.1.3.5. von Willebrand Factor
      • 10.1.3.6. Antithrombin
      • 10.1.3.7. Others
    • 10.1.4. Protease Inhibitors
      • 10.1.4.1. Alpha-1 Antitrypsin
      • 10.1.4.2. C1 Esterase Inhibitor
      • 10.1.4.3. Others
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Immunology
    • 10.2.2. Neurology
    • 10.2.3. Hematology
    • 10.2.4. Critical Care
    • 10.2.5. Pulmonology
    • 10.2.6. Infectious Disease
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By End-user
    • 10.3.1. Hospitals & Clinics
    • 10.3.2. Specialty Clinics & Infusion Centers
    • 10.3.3. Homecare Settings
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
      • 10.4.1.1. By Product
    • 10.4.2. South Africa
      • 10.4.2.1. By Product
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Product

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. CSL
    • 11.2.2. Grifols, S.A.
    • 11.2.3. Takeda Pharmaceutical Company Limited
    • 11.2.4. Octapharma AG
    • 11.2.5. Kedrion S.p.A.
    • 11.2.6. LFB Group
    • 11.2.7. ADMA Biologics, Inc.
    • 11.2.8. GC Biopharma corporate
    • 11.2.9. Beijing Tiantan Biological Products Co., Ltd.
    • 11.2.10. Shanghai RAAS Blood Products Co., Ltd.

List of Tables

  • Table 1: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulins, 2021-2034
  • Table 3: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 4: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Protease Inhibitors, 2021-2034
  • Table 5: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 6: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 7: Global Plasma Fractionation Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 9: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulins, 2021-2034
  • Table 10: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 11: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Protease Inhibitors, 2021-2034
  • Table 12: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 13: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 14: North America Plasma Fractionation Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: U.S. Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 16: Canada Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 17: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 18: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulins, 2021-2034
  • Table 19: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 20: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Protease Inhibitors, 2021-2034
  • Table 21: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 22: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 23: Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 24: U.K. Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 25: Germany Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 26: France Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 27: Spain Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 28: Italy Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 29: Scandinavia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 30: Rest of Europe Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 31: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 32: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulins, 2021-2034
  • Table 33: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 34: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Protease Inhibitors, 2021-2034
  • Table 35: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 36: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 37: Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 38: Japan Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 39: China Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 40: India Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 41: Australia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 42: Southeast Asia Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 43: Rest of Asia Pacific Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 44: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 45: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulins, 2021-2034
  • Table 46: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 47: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Protease Inhibitors, 2021-2034
  • Table 48: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 49: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 50: Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 51: Brazil America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 52: Mexico America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 53: Rest of Latin America Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 54: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 55: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Immunoglobulins, 2021-2034
  • Table 56: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Coagulation Factors, 2021-2034
  • Table 57: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Protease Inhibitors, 2021-2034
  • Table 58: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 59: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 60: Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 61: GCC Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 62: South Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034
  • Table 63: Rest of Middle East & Africa Plasma Fractionation Market Revenue (USD billion) Forecast, by Product 2021-2034

List of Figures

  • Figure 1: Global Plasma Fractionation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Plasma Fractionation Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Plasma Fractionation Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Plasma Fractionation Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Plasma Fractionation Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Plasma Fractionation Market Value (USD billion), by Product 2025 & 2034
  • Figure 7: North America Plasma Fractionation Market Value Share (%), by Product 2025
  • Figure 8: North America Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 9: North America Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 10: North America Plasma Fractionation Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Plasma Fractionation Market Value Share (%), by End User, 2025
  • Figure 12: North America Plasma Fractionation Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Plasma Fractionation Market Value Share (%), by Country, 2025
  • Figure 14: Europe Plasma Fractionation Market Value (USD billion), by Product 2025 & 2034
  • Figure 15: Europe Plasma Fractionation Market Value Share (%), by Product 2025
  • Figure 16: Europe Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 17: Europe Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 18: Europe Plasma Fractionation Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Plasma Fractionation Market Value Share (%), by End User, 2025
  • Figure 20: Europe Plasma Fractionation Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Plasma Fractionation Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Plasma Fractionation Market Value (USD billion), by Product 2025 & 2034
  • Figure 23: Asia Pacific Plasma Fractionation Market Value Share (%), by Product 2025
  • Figure 24: Asia Pacific Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Plasma Fractionation Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Plasma Fractionation Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Plasma Fractionation Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Plasma Fractionation Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Plasma Fractionation Market Value (USD billion), by Product 2025 & 2034
  • Figure 31: Latin America Plasma Fractionation Market Value Share (%), by Product 2025
  • Figure 32: Latin America Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 33: Latin America Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Plasma Fractionation Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Plasma Fractionation Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Plasma Fractionation Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Plasma Fractionation Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Product 2025 & 2034
  • Figure 39: Middle East & Africa Plasma Fractionation Market Value Share (%), by Product 2025
  • Figure 40: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Plasma Fractionation Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Plasma Fractionation Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Plasma Fractionation Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Plasma Fractionation Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Plasma Fractionation Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Plasma Fractionation Market Share (%), by Company, 2025